Antibiotic prophylaxis with 3-day course of prulifoxacin 600 mg in superficial bladder cancer patients undergoing Bacillus Calmette-Guerin (BCG) instillations: a prospective, randomised, open-label, controlled trial
Phase of Trial: Phase III
Latest Information Update: 29 Aug 2008
At a glance
- Drugs Prulifloxacin (Primary)
- Indications Bacterial infections; Urinary tract infections
- Focus Therapeutic Use
- 29 Aug 2008 New trial record.